Arcturus Therapeutics Holdings Inc. (ARCT): Total Liabilities
$57.16M
As of 2025-12-31
$52.50M
As of 2026-06-30
-31.8%
3-year compound annual growth
-6.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $57.16M | -44.6% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $103.09M | -31.7% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $150.89M | -16.2% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $180.07M | +9.4% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $164.60M | +106.0% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $79.90M | +41.8% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $56.35M | +84.4% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $30.56M | n/a | 2020-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $508.98M | -3.0% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $149.39M | +4.9% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $213.39M | +126.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $2.08B | +35.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
Compare ARCT, ADCT, NRIX, ETON side by side · Screen every company in Pharmaceutical Preparations ↗